Index of Microcirculatory Resistance: The Basics

Similar documents
For the NXT Investigators

MYOCARDIAL PERFUSION COMPUTED TOMOGRAPHY PhD course in Medical Imaging. Anne Günther Department of Radiology OUS Rikshospitalet

Non-invasive FFR Using Coronary CT Angiography and Computational Fluid Dynamics Predicts the Hemodynamic Significance of Coronary Lesions

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

FFR CT : Clinical studies

Listen to your heart: Good Cardiovascular Health for Life

Right Heart Catheterization from the Arm

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Perioperative Cardiac Evaluation

Efficient Evaluation of Chest Pain

Diagnostic and Therapeutic Procedures

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.

Cilostazol versus Clopidogrel after Coronary Stenting

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI

The Bioresorbable Vascular Stent Dr Albert Ko

Renovascular Hypertension

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Non-invasive functional testing in 2014

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

SECOND CARDIOLOGY JOINT SEMINAR. Rome, April 12-13, Cardiovascular Center OLV Clinic Aalst Belgium. and

Main Effect of Screening for Coronary Artery Disease Using CT

INTRODUCTION TO EECP THERAPY

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Duration of Dual Antiplatelet Therapy After Coronary Stenting

CARDIAC RISKS OF NON CARDIAC SURGERY

Subclavian Steal Syndrome By Marta Thorup

ECG may be indicated for patients with cardiovascular risk factors

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

The Essential Role of CT Planning and TEE Guidance to Optimize Device Deployment

Antiplatelet and Antithrombotics From clinical trials to guidelines

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)

ST Segment Elevation Nothing is ever as hard (or easy) as it looks

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

California Health and Safety Code, Section

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

Normal ranges of left ventricular global longitudinal strain: A meta-analysis of 2484 subjects

Antonio Colombo MD on behalf of the SECURITY Investigators

All patients presenting to the Emergency Department with symptoms suggestive of

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa Objectives. No disclosures, no conflicts

RITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY

Mattias Törnerud, Capio St Görans sjukhus AB, Stockholm. Invasiv tryckmätning FFR

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Non Invasive Testing for CAD

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Vascular Effects of Caffeine

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam

Section Four: Pulmonary Artery Waveform Interpretation

Section 8: Clinical Exercise Testing. a maximal GXT?

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.

Utilizing the Cath Lab for Cardiac Arrest

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology

PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline Genova Novembre 2015

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

Provider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code )

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY

38 year old female with mild obesity. She is planning an exercise program to loose weight. She has no other known risk factors for CAD.

Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time

Cardiovascular Guidelines for DOT Physical Exams By Maureen Collins MSN, APRN, BC

EMR Tutorial Acute Coronary Syndrome

Ischemic Heart Disease: Angina Pectoris

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

Prognostic impact of uric acid in patients with stable coronary artery disease

Implementing a Prehospital 12-Lead Program

Addendum to Clinical Review for NDA

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III

on behalf of the AUGMENT-HF Investigators

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

R.P. Zecchin*, J. Baihn, Y.Y. Chai, J. Hungerford, G. Lindsay, M. Owen, J. Thelander, D.L. Ross, C. Chow, A.R. Denniss. Westmead Hospital, Sydney,

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

URN: Family name: Given name(s): Address:

CPT CODE PROCEDURE DESCRIPTION. CT Scans CT HEAD/BRAIN W/O CONTRAST CT HEAD/BRAIN W/ CONTRAST CT HEAD/BRAIN W/O & W/ CONTRAST

MEDICAL POLICY No R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

Fort Hamilton Hospital Specialty: Cardiology Department of Medicine Delineation of Privileges

Is There A LIfe for DES after discontinuation of Clopidogrel

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

OCT STEMI: OCT guidance during stent implantation

Anticoagulants in Atrial Fibrillation

Understanding the Pain Trajectory During Treadmill Testing in Peripheral Artery Disease

CARDIAC CARE. Giving you every advantage

Cardiovascular Practice Quality Improvement : Role of ACC-NCDR and HIT

Transcription:

Index of Microcirculatory Resistance: The Basics William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit Company St. Jude Medical, Medtronic, NHLBI Medtronic Minor stock options: HeartFlow

Assessment of the Microvasculature Diagnostic Challenge Epicardial CAD Lanza and Crea. Circulation 2010;121:2317-2325.

Assessment of the Microvasculature Diagnostic Challenge Epicardial CAD Microvascular Dysfunction Lanza and Crea. Circulation 2010;121:2317-2325.

Assessment of the Microvasculature Extremely challenging diagnosis Heterogeneous patient population Variety of pathogenetic mechanisms Poor anatomic resolution Potentially patchy nature of the disease Therefore, assessment of the microvasculature is primarily functional and not anatomic

Evaluating the Microcirculation in the Cath Lab TIMI Myocardial Perfusion Grade:

Evaluating the Microcirculation in the Cath Lab TIMI Myocardial Perfusion Grade: Easy to obtain Specific for microvasculature Predictive of outcomes in large studies Drawbacks: Qualitative Interobserver variability Not as useful in smaller studies

Doppler Wire Coronary Flow Reserve CFR = Hyperemic Flow Resting Flow

Coronary Wire-Based Assessment Coronary Flow Reserve Not microvascular specific No clearly defined normal value Affected by resting hemodynamics Pijls NHJ and De Bruyne B, Coronary Pressure Kluwer Academic Publishers, 2000

Index of Microcirculatory Resistance IMR

Index of Microcirculatory Resistance Potential Advantages: Readily available in the cath lab Specific for the microvasculature Quantitative and reproducible Predictive of outcomes

Estimation of Coronary Flow Proximal Thermistor Distal Thermistor/Pressure Sensor Calculation of mean transit time De Bruyne, et al. Circulation 2002;104:2003

Derivation of IMR: Resistance = Pressure / Flow Pressure = P d -P v Flow 1 / T mn IMR = P d -P v / (1 / T mn ) IMR = P d x T mn at maximal hyperemia Circulation 2003;107:3129-3132.

Practical Measurement of IMR IMR = P d x Hyperemic T mn = 89 x 0.37 = 33

IMR Case Example Cardiac transplant recipient enrolled in study evaluating ACE inhibition

IMR Case Example Cardiac transplant recipient enrolled in study evaluating ACE inhibition

Accessing IMR System Options CFR

Flushing the System

Resting T mn Measurements

Hyperemic T mn Measurements

Calculating IMR IMR = P d x Hyp T mn IMR = 59 x 0.39 IMR = 23

Animal Validation of IMR Guide Pressure Wire Radio-opaque Occluder LAD Flow Probe Circulation 2003;107:3129-3132.

IMR Animal Validation of IMR 30 25 p = 0.002 20 15 10 5 0 Normal Microcirculation Abnormal Microcirculation Circulation 2003;107:3129-3132

TMR Animal Validation of IMR 1 0.8 p = 0.0001 0.6 0.4 0.2 0 Normal Microcirculation Abnormal Microcirculation Circulation 2003;107:3129-3132

% Change after Disruption of the Microcirculation Animal Validation of IMR 300 250 p = NS 200 150 100 IMR TMR 50 0 Total Group Stenosis Absent Stenosis Present Circulation 2003;107:3129-3132.

Reproducibility of IMR Effect of Pacing on FFR/CFR/IMR Effect of Blood Pressure on FFR/CFR/IMR Change in LV Contractility and FFR/CFR/IMR Ng, et al. Circulation 2006;113:2054-61.

Reproducibility of IMR Mean correlation coefficients of IMR, CFR and FFR values comparing baseline measurement with each hemodynamic intervention P<0.05 P<0.05 Ng, et al. Circulation 2006;113:2054-61.

Reproducibility of IMR Coefficient of variation between pairs of baseline values of IMR and CFR P<0.01 Ng, et al. Circulation 2006;113:2054-61.

Reproducibility of IMR Correlation between IMR and cardiac MR assessment of microvascular obstruction in 108 patients after STEMI Repeated IMR measurements obtained by 4 different operators in 12 STEMI patients were highly correlated (r=0.99, P<0.001), with a mean difference between IMR measurements of 0.01 (mean standard error 1.59 [95% CI 3.52 to 3.54], P=0.48). Payne, et al. J Am Heart Assoc 2012;1:e002246.

IMR: Normal Value An IMR 25 is considered normal The mean IMR measured in 15 subjects (22 arteries) without any evidence of atherosclerosis and no/minimal risk factors was 19±5. The mean IMR measured in 18 subjects with normal stress tests and normal coronary angiography was 18.9±5.6. Melikian, et al. Eurointervention 2010;5:939-945 Luo, et al. Circ Cardiovasc Interv 2014;7:

IMR and Epicardial Stenosis Role of collaterals when measuring IMR in patients with significant epicardial stenosis Resistance = Pressure / Q myo Q myo = Q cor + Q coll Simplified IMR = P d x T mn But T mn is inversely proportional to coronary flow Catheter Cardiovasc Interv 2004;62:56-63.

Importance of Collaterals when Measuring IMR Q cor Q coll P d R myo Catheter Cardiovasc Interv 2004;62:56-63.

Importance of Collaterals when Measuring IMR Q cor Q coll P d IMR app Flow s more than it should, T mn s and IMR app = P d x T mn s To measure true IMR, must measure coronary wedge pressure to incorporate collateral flow IMR = P d x T mn x (FFR cor / FFR myo ) Catheter Cardiovasc Interv 2004;62:56-63.

IMR is not affected by epicardial stenosis severity: Animal Validation Circulation 2004;109:2269-2272

stenosis stenosis FFR = 0.53± 0.19 FFR 0.53± 0.19 IMR is not affected by epicardial stenosis severity: After After After stenting stenting stenting FFR = 0.90 ± 0.12 FFR 0.90 0.12 FFR = 0.90 ± 0.12 Human Validation FFR = 0.84 ± 0.08 10% AS FFR 0.84 0.08 10% AS FFR 0.84 ± 0.08 10% AS IMR = 22 ± 15 IMR 22 15 IMR = 22 ± 15 50% AS 50% AS 50% AS 75% AS 75% AS 75% AS FFR = 0.69 ± 0.09 FFR 0.69 0.09 FFR 0.69 ± 0.09 IMR = 23 ± 14 IMR 23 14 IMR = 23 ± 14 FFR = 0.52 ± 0.11 FFR 0.52 0.11 FFR 0.52 ± 0.11 IMR = 23 ± 14 IMR 23 14 IMR = 23 ± 14 Aarnoudse, et al. Circulation 2004;110:2137-42

IMR IMR is not affected by epicardial stenosis severity: 45 Human Validation 40 35 IMR app 30 25 IMR 20 15 1.0 0.9 0.8 0.7 0.6 0.5 0.4 FFR Aarnoudse, et al. Circulation 2004;110:2137-42

Estimating True IMR without Wedge IMR = P d x T mn x (FFR cor / FFR myo ) IMR = P d x T mn x ((P d -P w )/(P a -P w ) / (P d /P a )) If there is a relationship between FFR cor and FFR myo, perhaps we can estimate FFR cor without having to measure the coronary wedge pressure. Yong, et al. J Am Coll Cardiol Intv 2013;6:53-8.

Estimating True IMR without Wedge In a derivation cohort of 50 patients, a strong linear relationship was found between FFR cor and FFR myo. Yong, et al. J Am Coll Cardiol Intv 2013;6:53-8.

Estimating True IMR without Wedge In a validation cohort of 72 patients, there was no significant difference in IMR with estimate FFR cor or measured FFR cor. Yong, et al. J Am Coll Cardiol Intv 2013;6:53-8.

Estimating True IMR without Wedge In a validation cohort of 72 patients, there was no significant difference in IMR with estimate FFR cor or measured FFR cor. Yong, et al. J Am Coll Cardiol Intv 2013;6:53-8.

Clinical Application of IMR 59 year old man with HTN, dyslipidemia and chest pain with emotional stress and septal ischemia on Nuclear Scan

IMR = 76 x 0.70 = 53

Chest Pain and Normal Coronaries 139 patients referred for coronary angiography because of symptoms and/or abnormal stress test and found to have normal appearing coronaries FFR, IMR, CFR, IVUS and acetylcholine challenge were performed down the LAD Lee BK, et al. Circulation. 2013;128:A19113

Chest Pain and Normal Coronaries Patient Characteristic n=139 Age (years) 54 ±11 Female 77% Hypertension 53% Diabetes 23% Dyslipidemia 63% Tobacco Use 8% Lee BK, et al. Circulation. 2013;128:A19113

Chest Pain and Normal Coronaries The mean IMR was 19.6 ±9.1 Microvascular dysfunction was present in 21% (defined as IMR 25) Predictors of microvascular dysfunction were age, diabetes, HTN, and BMI Lee BK, et al. Circulation. 2013;128:A19113

Chest Pain and Normal Coronaries 5% of patients had an FFR of the LAD 0.80 44% had epicardial endothelial dysfunction 58% had a myocardial bridge 24% had nonischemic FFR, normal IMR, no endothelial dysfunction and no bridge Lee BK, et al. Circulation. 2013;128:A19113

IMR Before PCI in Stable Patients IMR measured before PCI in 50 stable patients undergoing LAD PCI Ng, et al. Circ Cardiovasc Interv 2012;5:515-22.

Predictive Value of IMR after PCI for STEMI IMR predicts peak CK in patients with STEMI J Am Coll Cardiol 2008;51:560-5

IMR and Outcomes post STEMI Multicenter study evaluating relationship between IMR and longer-term outcomes in 253 STEMI patients Circulation 2013; 127:2436-2441.

IMR post Stem Cell Therapy IMR measured in 15 patients with ischemic cardiomyopathy before and 6 months after intracoronary stem cell delivery Tayyareci, et al. Angiology 2008;59:145

IMR post Statin Therapy IMR measured after PCI in 80 patients randomized to either 1 month pretreatment with pravastatin or placebo Fujii, et al. J Am Coll Cardiol Intv 2011; 4:513-20.

IMR post ACE Inhibitor Therapy 40 patients randomized to IC enalaprilat or placebo prior to PCI Mangiacapra, et al. J Am Coll Cardiol 2013; 61:615-21.

Limitations of IMR Invasive Interpatient and intervessel variability? Sensor distance Independent of epicardial stenosis Coronary wedge pressure

Conclusion Take Home Messages: The microvasculature is a complex entity, which is challenging to investigate. Measurement of IMR is easy, specific for the microvasculature, quantitative, reproducible, and independent of hemodynamic changes. Measurement of IMR may help guide treatment in patients with normal coronaries and chest pain. IMR predicts outcomes in acute MI; emerging data suggest its utility in stable PCI patients, as well.